Filgrastim treatment of HIV-infected patients improves neutrophil function.
The effect of Filgrastim (recombinant methionyl human granulocyte colony-stimulating factor) treatment on neutrophil function was studied in HIV-infected patients. Filgrastim therapy significantly increased oxidative capacity of neutrophils, increased bacterial killing, and reduced accelerated apoptosis of neutrophils observed in this patient population.
Pitrak
D L
DL
Section of Infectious Diseases, University of Illinois at Chicago, 60612, USA.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000473:pathology; D017209:Apoptosis / Q000187:drug effects; D001424:Bacterial Infections / Q000209:etiology / Q000517:prevention & control*; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans; D009503:Neutropenia / Q000209:etiology* / Q000473:pathology; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D011994:Recombinant Proteins; D016897:Respiratory Burst / Q000187:drug effects
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim